Elias Zerhouni - BG Foods Independent Director
| DHR Stock | EUR 6.91 0.01 0.14% |
Director
Dr. Elias A. Zerhouni, M.D. is Independent Director of the Company. He has served as President, Global Research Development, for SanofiAventis, a global pharmaceutical company, since January 2011. From 1996 to 2002, Dr. Zerhouni served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research and Executive Vice Dean of the Johns Hopkins School of Medicine. From 2002 to November 2008, Dr. Zerhouni served as director of the National Institutes of Health, and from November 2008 to December 2010 he provided advisory and consulting services to various nonprofit and other organizations as Chairman and President of Zerhouni Holdings. Dr. Zerhouni, a physician, scientist and worldrenowned leader in radiology research, is widely viewed as one of the leading authorities in the United States on emerging trends and issues in medicine and medical care. These insights, as well as his deep, technical knowledge of the research and clinical applications of medical technologies, are of considerable importance given Danahers strategic expansion in the medical technologies markets since 2009.
| Age | 67 |
| Tenure | 15 years |
Elias Zerhouni Latest Insider Activity
Tracking and analyzing the buying and selling activities of Elias Zerhouni against BG Foods stock is an integral part of due diligence when investing in BG Foods. Elias Zerhouni insider activity provides valuable insight into whether BG Foods is net buyers or sellers over its current business cycle. Note, BG Foods insiders must abide by specific rules, including filing SEC forms every time they buy or sell BG Foods'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Elias Zerhouni over a year ago Acquisition by Elias Zerhouni of 216 shares of Danaher subject to Rule 16b-3 |
BG Foods Leadership Team
Elected by the shareholders, the BG Foods' board of directors comprises two types of representatives: BG Foods inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DHR. The board's role is to monitor BG Foods' management team and ensure that shareholders' interests are well served. BG Foods' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BG Foods' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian Ellis, Senior Vice President, Chief Compliance Officer, General Counsel | ||
| Rainer Blair, President, Chief Executive Officer, Director | ||
| Raymond Stevens, Independent Director | ||
| Angela Lalor, Senior Vice President - Human Resources | ||
| Jessica Mega, Independent Director | ||
| Steven Rales, Chairman of the Board | ||
| Pardis Sabeti, Independent Director | ||
| Alan Spoon, Independent Director | ||
| Robert Lutz, Senior Vice President Chief Accounting Officer | ||
| William King, Senior Vice President - Strategic Development | ||
| Matthew McGrew, Chief Financial Officer, Executive Vice President | ||
| Thomas Joyce, President, Chief Executive Officer, Director | ||
| Mitchell Rales, Director, Chairman of the Executive Committee | ||
| Walter Lohr, Independent Director | ||
| JoseCarlos GutierrezRamos, Senior Vice President Chief Scientific Officer | ||
| John Schwieters, Independent Director | ||
| Linda Filler, Lead Independent Director | ||
| Teri ListStoll, Independent Director | ||
| Joakim Weidemanis, Executive Vice President | ||
| Daniel Raskas, Senior Vice President - Corporate Development | ||
| Daniel Comas, CFO, Executive Vice President | ||
| Elias Zerhouni, Independent Director | ||
| Jennifer Honeycutt, Executive Vice President |
DHR Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BG Foods a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 3.15 B | |||
| Price To Book | 1.07 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 2.06 B | |||
| EBITDA | 297.4 M | |||
| Net Income | 67.36 M | |||
| Total Debt | 2.27 B | |||
| Cash Flow From Operations | 93.88 M | |||
| Number Of Employees | 26 | |||
| Total Asset | 3.83 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in DHR Stock
When determining whether BG Foods is a strong investment it is important to analyze BG Foods' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BG Foods' future performance. For an informed investment choice regarding DHR Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in BG Foods. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade DHR Stock refer to our How to Trade DHR Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.